Noninvasive versus histologic detection of gastric atrophy in a hispanic population in North America

被引:64
作者
Graham, DY
Nurgalieva, ZZ
El-Zimaity, HMT
Opekun, AR
Campos, A
Guerrero, L
Chavez, A
Cardenas, V
机构
[1] Univ Texas, Sch Publ Hlth, Div Epidemiol, El Paso, TX 79902 USA
[2] Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA
[3] Baylor Coll Med, Houston, TX 77030 USA
[4] Gen Hosp Reg 6, Mexican Inst Social Secur, Chihuahua, Mexico
关键词
D O I
10.1016/j.cgh.2005.11.003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Cancer risk is directly correlated with the severity and extent of mucosal atrophy, making identification of atrophy a goal in cancer prevention programs. The aim of this study was to compare targeted histology with noninvasive testing for the identification of antral and/or corpus atrophy in North America. Methods: In a cross-sectional study of a random sample of households, 8 gastric biopsy specimens were obtained from defined locations in the antrum and corpus. Biopsies were scored for the presence of Helicobacter pylori and gastric atrophy (defined as loss of normal glandular components). Atrophy was scored by using the Sydney system and a system based on the number and location of corpus biopsies with atrophy. Patients' sera were examined for pepsinogen I, pepsinogen II, and gastrin-17 (fasting and stimulated). Results: One hundred eighty volunteers, approximately 30 per age group and ranging in age from 18-82 years, participated. There were 76 men. The overall weighted prevalence of a corpus atrophy was 4.7% (95% confidence interval, 2.3-7.0). There was a significant inverse relationship between the grade of corpus atrophy and the pepsinogen I/pepsinogen II ratio (R = -0.31, P <.01). We failed to confirm the usefulness of the proposed algorithm by using gastrin-17, H pylori serology, and serum pepsinogens to categorize the gastric histology. The Sydney system underestimated the prevalence of corpus atrophy by approximately 25%. Conclusion: Noninvasive testing is both possible and practical by using pepsinogen assays for the identification of the precancerous condition of moderate to severe corpus atrophy in North American Hispanic patients.
引用
收藏
页码:306 / 314
页数:9
相关论文
共 34 条
[1]  
Aoki K, 1997, J Epidemiol, V7, P143
[2]   Patterns of gastric atrophy in intestinal type gastric carcinoma [J].
El-Zimaity, HMT ;
Ota, H ;
Graham, DY ;
Akamatsu, T ;
Katsuyama, T .
CANCER, 2002, 94 (05) :1428-1436
[3]   Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis [J].
ElZimaity, HMT ;
Graham, DY ;
AlAssi, MT ;
Malaty, H ;
Karttunen, TJ ;
Graham, DP ;
Huberman, RM ;
Genta, RM .
HUMAN PATHOLOGY, 1996, 27 (01) :35-41
[4]   HELICOBACTER-PYLORI INFECTION, SERUM PEPSINOGEN LEVEL AND GASTRIC-CANCER - A CASE-CONTROL STUDY IN JAPAN [J].
FUKUDA, H ;
SAITO, D ;
HAYASHI, S ;
HISAI, H ;
ONO, H ;
YOSHIDA, S ;
OGURO, Y ;
NODA, T ;
SATO, T ;
KATOH, M ;
TERADA, M ;
SUGIMURA, T .
JAPANESE JOURNAL OF CANCER RESEARCH, 1995, 86 (01) :64-71
[5]  
Graham David Y., 2000, Journal of Gastroenterology, V35, P90
[6]   The time to eradicate gastric cancer is now [J].
Graham, DY ;
Shiotani, A .
GUT, 2005, 54 (06) :735-738
[7]   Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: A model [J].
Graham, DY .
GASTROENTEROLOGY, 1997, 113 (06) :1983-1991
[8]   Helicobacter pylori and perturbations in acid secretion: End of the beginning [J].
Graham, DY .
GASTROENTEROLOGY, 1996, 110 (05) :1647-1650
[9]  
Graham DY, 1997, HELICOBACTER, V2, pS44
[10]  
GRAHAM DY, 2002, GUT BRAIN PEPTIDES N, P83